✦ LIBER ✦

Vaccination with an altered MBP peptide induces a persistent immune response

✍ Scribed by J.P. Antel; Y. Qin; D. Zhang; P. Crowe; P. Conlon

Book ID: 114138405
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 131 KB
Volume: 90
Category: Article
ISSN: 0165-5728
DOI: 10.1016/s0165-5728(98)91288-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simvastatin enhances immune responses to

Simvastatin enhances immune responses to Aβ vaccination and attenuates vaccination-induced behavioral alterations

✍ Jinghong Kou; Hong-Duck Kim; JingJi Jin; Dongfeng Cao; Ling Li; Robert Lalonde; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 383 KB

Persistence of Immune Responses to Alter

Persistence of Immune Responses to Altered and Native Myelin Antigens in Patients with Multiple Sclerosis Treated with Altered Peptide Ligand

✍ H.J. Kim; J.P. Antel; P. Duquette; D.G. Alleva; P.J. Conlon; A. Bar-Or 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Rectal and vaginal immunization with a m

Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses

✍ Hidenori Kato; Hiroki Bukawa; Eri Hagiwara; Ke-Qin Xin; Kenji Hamajima; Susumu K 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 489 KB

Xenogeneic Human Tyrosinase DNA Vaccinat

Xenogeneic Human Tyrosinase DNA Vaccination Induces Specific Immune Response in Dogs with Advanced Malignant Melanoma

✍ J. Liao; P. Gregor; F. Orlandi; D. M. Craft; C. Leung; A. N. Houghton; J. D. Wol 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

Mucosal immunization with a DNA vaccine

Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site

✍ Bin Wang; Kesen Dang; Michael G. Agadjanyan; Vasantha Srikantans; Feng Li; Kenne 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 661 KB

Immunization with a P53 synthetic long p

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

✍ Ninke Leffers; Annechien J.A. Lambeck; Marloes J.M. Gooden; Baukje-Nynke Hoogebo 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 255 KB

## Abstract The prognosis of ovarian cancer, the primary cause of death from gynecological malignancies, has only modestly improved over the last decades. Immunotherapy is one of the new treatment modalities explored for this disease. To investigate safety, tolerability, immunogenicity and obtain a